S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa

CollPlant Biotechnologies Stock Price, News & Analysis (NASDAQ:CLGN)

$5.17
-0.18 (-3.36%)
(As of 12/8/2023 ET)
Compare
Today's Range
$5.15
$5.45
50-Day Range
$4.98
$6.64
52-Week Range
$4.70
$13.97
Volume
2,502 shs
Average Volume
N/A
Market Capitalization
$57.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.88

CollPlant Biotechnologies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
226.4% Upside
$16.88 Price Target
Short Interest
Healthy
0.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.11 to ($0.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

558th out of 932 stocks

Surgical Appliances & Supplies Industry

15th out of 17 stocks


CLGN stock logo

About CollPlant Biotechnologies Stock (NASDAQ:CLGN)

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

CLGN Stock Price History

CLGN Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Recap: CollPlant Biotechnologies Q3 Earnings
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Collplant Holdings (CLGN) Gets a Buy from H.C. Wainwright
Preview: CollPlant Biotechnologies's Earnings
See More Headlines
Receive CLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/24/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/03/2024

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLGN
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.88
High Stock Price Target
$22.75
Low Stock Price Target
$11.00
Potential Upside/Downside
+226.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-16,920,000.00
Pretax Margin
-62.80%

Debt

Sales & Book Value

Annual Sales
$300,000.00
Book Value
$2.91 per share

Miscellaneous

Free Float
10,022,000
Market Cap
$57.34 million
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Yehiel Tal (Age 71)
    CEO & Director
    Comp: $865k
  • Mr. Eran Rotem CPA (Age 55)
    Deputy CEO & CFO
    Comp: $651k
  • Prof. Oded Shoseyov (Age 67)
    Founder & Chief Scientist
    Comp: $384k
  • Mr. Oren Fahimipoor (Age 41)
    Vice President of Operations
  • Ms. Hadas Dreiher Horowitz (Age 46)
    Vice President of Human Resources
  • Dr. Elana Gazal (Age 48)
    Vice President of Research & Development














CLGN Stock Analysis - Frequently Asked Questions

Should I buy or sell CollPlant Biotechnologies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLGN shares.
View CLGN analyst ratings
or view top-rated stocks.

What is CollPlant Biotechnologies' stock price target for 2024?

2 brokerages have issued twelve-month target prices for CollPlant Biotechnologies' stock. Their CLGN share price targets range from $11.00 to $22.75. On average, they expect the company's share price to reach $16.88 in the next year. This suggests a possible upside of 226.4% from the stock's current price.
View analysts price targets for CLGN
or view top-rated stocks among Wall Street analysts.

How have CLGN shares performed in 2023?

CollPlant Biotechnologies' stock was trading at $8.35 at the beginning of 2023. Since then, CLGN shares have decreased by 38.1% and is now trading at $5.17.
View the best growth stocks for 2023 here
.

Are investors shorting CollPlant Biotechnologies?

CollPlant Biotechnologies saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 17,800 shares, a decrease of 15.6% from the October 31st total of 21,100 shares. Based on an average daily trading volume, of 14,600 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.2% of the shares of the company are sold short.
View CollPlant Biotechnologies' Short Interest
.

When is CollPlant Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our CLGN earnings forecast
.

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) released its earnings results on Thursday, August, 24th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.83. The business had revenue of $10.18 million for the quarter, compared to analysts' expectations of $0.26 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 20.61% and a negative net margin of 62.80%. During the same quarter last year, the firm earned ($0.39) earnings per share.

What other stocks do shareholders of CollPlant Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA), Boingo Wireless (WIFI), Allena Pharmaceuticals (ALNA), Advanced Micro Devices (AMD), Energy Transfer (ET), HTG Molecular Diagnostics (HTGM), OPKO Health (OPK), Ovid Therapeutics (OVID) and

When did CollPlant Biotechnologies IPO?

(CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.

Who are CollPlant Biotechnologies' major shareholders?

CollPlant Biotechnologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (4.31%), Villere ST Denis J & Co. LLC (2.71%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CLGN) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -